Key result
The Hemopump, a miniature axial flow temporary left ventricular assist blood pump placed transvalvularly across the aortic valve, has met design challenges and shows potential as a safe clinical device.
Answers are grounded in this paper and cite their sources.
The Hemopump represents a novel percutaneous temporary left ventricular assist device with promising early clinical potential.
A unique cardiac prothesis device is currently undergoing clinical trials. Called the Hemopump, this device is a radical new design of a temporary left ventricular assist blood pump. It uses a miniature (7 mm diameter) axial flow pump placed transvalvular across the aortic valve which pumps blood from the left ventricle to the aorta. Mechanical power from an external motor is transmitted percutaneously to the pump by a flexible cable contained within a catheter-like sheath. This arrangement allows the pump to be placed through a femoral artery cutdown without requiring major surgery. Development of the Hemopump concept presented significant challenges in pump hydraulic design, bearing, and seal design, as well as materials selection and miniature parts fabrication. Clinical trial results thus far indicate these challenges have been well met and that the Hemopump has the potential to become a widely used safe and effective clinical device.
No takes yet. Share an insight, caveat, or question.
Butler et al. (1990) reported a review. Hemopump was evaluated. The Hemopump, a miniature axial flow temporary left ventricular assist blood pump placed transvalvularly across the aortic valve, has met design challenges and shows potential as a safe clinical device.
Synapse has enriched 10 related papers. Consider them for comparative context: